Medication info

HaniBanju (Ibandronic Acid Sodium Monohydrate) (Pre-filled)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 3mL
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
It is a colorless and transparent solution in a colorless and transparent glass pre-filled syringe with a disposable needle attached.
Packaging
1 package (3mL) x 1 pre-filled syringe
Approval status
Active

MFDS item code 201605329 · Notified 2016.08.31 · Insurance code 657805921

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this drug is not recommended in patients whose serum creatinine is greater than 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience in these patients is insufficient. Older adults No dose adjustment is necessary.
Child administration
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis, which commonly occurs in postmenopausal women. After menopause, the decrease in female hormones can weaken bones, and this drug increases bone density to reduce the risk of fractures. It plays an important role in the treatment of osteoporosis, improving bone health and enhancing the quality of life in daily activities. Therefore, it is effective in preventing and treating postmenopausal osteoporosis.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this drug is not recommended in patients whose serum creatinine is greater than 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience in these patients is insufficient. Older adults No dose adjustment is necessary.

Child administration

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This medication must be administered intravenously, and it must be used with great caution when administering it into an artery or around a vein as it may cause tissue damage. It should not be used in patients with an allergy to this drug or its components, or in patients with untreated hypocalcemia. During the use of this drug, some patients may experience gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation. Musculoskeletal symptoms such as myalgia, arthralgia, and musculoskeletal pain have also been reported, and symptoms such as fatigue, headache, and rash may occur as well. Some patients may temporarily experience flu-like symptoms such as arthralgia, myalgia, fever, chills, fatigue, nausea, appetite loss, and bone pain. Severe allergic reactions or anaphylaxis may occur, so if these symptoms arise during administration, treatment should be stopped immediately and appropriate care should be sought. This drug can temporarily lower serum calcium levels, so it is essential to treat hypocalcemia or bone and mineral metabolism disorders before administration. Proper intake of calcium and vitamin D is required during the treatment period, and supplements should be taken if necessary. Particular caution should be taken in patients undergoing dental treatment or those with risk factors due to the risk of jaw osteonecrosis, and an oral examination and preventive dental treatment should be considered before administration. During the administration of this drug, excessive dental procedures should be avoided, and if symptoms associated with osteonecrosis arise, a specialist should be consulted. This drug can rarely cause osteonecrosis of the external auditory canal, so if ear infections or pain persist, inform the doctor. Long-term use may pose risks for atypical fractures, particularly femoral fractures, so if there is pain in the thigh or groin, assessment should be promptly obtained. It may affect kidney function, so patients with kidney disease or those taking medications affecting the kidneys should have regular check-ups with their doctor. It is advisable not to use this drug in pregnant or lactating women, as safety has not been established. In the case of overdose, monitoring kidney and liver functions is essential, and if side effects like hypocalcemia occur, appropriate treatment should be sought. This drug should not be mixed with calcium-containing solutions or other intravenous medications and must be administered only with the specified solution. Used needles and syringes should not be reused and must be disposed of safely.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • dyspepsia
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • muscle pain
  • influenza-like illness
Show 28 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reaction
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reaction
  • angioedema
  • facial swelling
  • edema
  • urticaria
  • uveitis
  • episcleritis
  • sclertitis
  • anaphylactic reaction
  • shock
  • exacerbation of asthma
  • Stevens-Johnson syndrome
  • erythema multiforme
  • vesicular dermatitis
  • atypical subtrochanteric fracture
  • intertrochanteric femoral fracture
  • external auditory canal osteonecrosis
  • jaw osteonecrosis
  • acute renal failure
  • sensory impairment

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, ideally at a temperature between 1 degree to 30 degrees Celsius. Proper storage preserves the drug's efficacy and prevents deterioration.

Appearance and packaging

Appearance

It is a colorless and transparent solution in a colorless and transparent glass pre-filled syringe with a disposable needle attached.

Package unit

1 package (3mL) x 1 pre-filled syringe

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.